CAR T-cell Therapy Market worth $29.0 billion by 2029
The report "CAR T-cell Therapy Market by Product (Abecma, Breyanzi, Carvykti, Yescarta, Tecartus, Kymriah), Target Antigen (CD19, BCMA), Indication (Multiple Myeloma, Leukemia, Lymphoma), Demographic (Adult, Pediatric), End User & Region - Global Forecast to 2029", is projected to reach USD 29.0 billion by 2029 from USD 5.5 billion in 2024, at a CAGR of 39.6% during the forecast period of 2024 to 2029.
Browse 281 market data Tables and 48 Figures spread through 265 Pages and in-depth TOC on "CAR T-cell Therapy Market by Product (Abecma, Breyanzi, Carvykti, Yescarta, Tecartus, Kymriah), Target Antigen (CD19, BCMA), Indication (Multiple Myeloma, Leukemia, Lymphoma), Demographic (Adult, Pediatric), End User & Region - Global Forecast to 2029"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/car-t-cell-therapy-market-47772841.html
The CAR T-cell therapy market is predicted to grow at a CAGR of 39.6% during the forecast period of 2024 to 2029. The important factors impacting market growth are the rising prevalence of cancer and increasing funding and investments for therapy development. Additionally, the rising technological advancements in CAR T-cell therapies is likely to uplift market growth in coming years.
Products segment held the highest share of the CAR T-cell therapy market
Based on the products, the CAR T-cell therapy market is segmented into Abecma (idecabtagene vicleucel), Breyanzi (lisocabtagene maraleucel), Carvykti (ciltacabtagene autoleucel), Yescarta (axicabtagene ciloleucel), Tecartus (brexucabtagene autoleucel), Kymriah (tisagenlecleucel) and other products. YESCARTA accounted for the largest share of the CAR T-cell therapy market. YESCARTA’s manufacturer Gilead Sciences Inc. secured regulatory approvals for Yescarta in key international markets, facilitating global market penetration. This broad geographical footprint increases patient access and revenue potential, solidifying Yescarta's position as one of the leading CAR T-cell therapy globally.
High growth of indications segment attributed to B-Cell Lymphoma (BCL).
Based on indications, the CAR T-cell therapy market is broadly segmented into Acute Lymphoblastic Leukemia (ALL), Multiple Myeloma, B-Cell Lymphoma (BCL), and other indications. In 2023, B-Cell Lymphoma (BCL) accounted for the largest share of the CAR T-cell therapy market. The high growth of this segment is attributed to the increasing prevalence of B-cell Lymphomas providing a major patient pool for the growth of CAR T-cell therapies.
CD19 segment dominates the taget segment of CAR T-cell therapy market
Based on the target, the CAR T-cell therapy market is segmented into BCMA, CD19, and other targets. In 2023, the CD19 segment accounted for the highest share of the CAR T-cell therapy market. CD19 is a protein expressed on the surface of B-cells, including malignant B-cell lymphomas. These cancers are relatively common, making CD19 a prominent target for CAR T-cell therapies, thereby driving the growth of the market.
North America exhibited the most substantial market growth during the forecasted period.
North America accounted for the largest share of of 69.6% of the CAR T-cell therapy market in 2023. The North America market is projected to reach a value of USD 19,741.3 million by 2029 from an estimated value of USD 3,703.8 million in 2024, at a CAGR of 39.7% during the forecast period. The region leads the CAR T-cell therapy market due to advanced healthcare infrastructure, early adoption due to early US FDA regulatory approvals of all CAR T-cell thrapy drugs and significant investments in CAR T-cell therapy research and development.
The global CAR T-cell therapy market features key market players actively competing for market share, such as Bristol-Myers Squibb Company (US), Gilead Sciences, Inc. (US), Novartis AG (Switzerland), Johnson & Johnson (US), and JW (Cayman) Therapeutics Co. Ltd (China).
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the CAR T-cell Therapy Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
